Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

Exploring Analgesics as a Key Painkiller Types & Their Role in Pain ReliefUnited States, New York, Feb. 04, 2025 (GLOBE ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Most states allow some form of "medical marijuana". Medical marijuana is especially popular with pain patients, many of whom ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine) 50 milligram oral tablets, a groundbreaking ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

Am J Health Syst Pharm. 2007;64(11):1148-1152. Health care organizations around the nation have been working to reduce the use of meperidine as a first-line agent for pain management. Despite the ...

The new pill, developed by Vertex Pharmaceuticals, is intended for short-term pain relief following surgery or injury, the ...

Therefore, the Anti-NGF analgesic drug DS002 has the potential to become a promising drug in the field of analgesia, providing pain patients with an efficient treatment option without adverse effects.